Efficacy of third-line therapy using bevacizumab in a patient with metastatic colorectal cancer

J. Gaulin MD,* R. Kotb MD,* E. Turcotte MD,* G. Berard BPharm MSc,* B. Sawan MD,* G. Schmutz MD,* and P. Beauregard MD*

ABSTRACT
Bevacizumab is currently approved in association with first- and second-line 5-fluorouracil–based chemotherapy regimens for patients with metastatic colorectal cancer. Few data about the usefulness of bevacizumab in third-line settings are available. We describe a patient refractory to FOLFIRI and FOLFOX chemotherapy regimens who showed a dramatic and durable response to bevacizumab and FOLFIRI. We also review and discuss the available literature.

KEY WORDS
Colorectal cancer, bevacizumab, third-line therapy

1. INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy affecting men and women in Canada. Many patients present with metastatic disease, and a significant proportion of those treated with cure-intended surgery, with or without adjuvant chemotherapy, eventually relapse.

Significant improvement in chemotherapy for metastatic colorectal cancer (mCRC) has been achieved with the addition of irinotecan and oxaliplatin to 5-fluorouracil (5FU)–based therapy. More recently, targeted agents such as bevacizumab, cetuximab, and panitumumab have shown promising results, especially in combination with conventional chemotherapy.

Bevacizumab is a human recombinant monoclonal antibody directed against the vascular endothelial growth factor. Combined with 5FU-based regimens, bevacizumab has been shown to improve outcome in the setting of first- and second-line chemotherapy, and it is now considered a standard of care for patients in those settings. Data concerning the usefulness of bevacizumab in the third-line treatment of mCRC are limited.

Here, we report on a patient diagnosed with mCRC who progressed after the usual FOLFIRI and FOLFOX regimens, but who achieved a significant tumour response with bevacizumab-containing third-line treatment.

2. CASE REPORT
A 49-year-old man with an unremarkable medical history was diagnosed with metastatic cecal adenocarcinoma in June 2005. The tumour was invading the right iliac fossa up to the superficial abdominal wall. This patient underwent extensive right hemicolectomy with partial abdominal wall resection on June 21.

Pathology studies revealed a 7×8-cm infiltrative grade III mucinous adenocarcinoma. Of the 36 lymph nodes collected, 7 were infiltrated, and some showed capsular rupture. Lymphatic vascular permeation and a peritumoural metastatic peritoneal implant were present. The right lateral resection margin was positive. Serum carcinoembryonic antigen (CEA) dropped to 8.7 µg/L from 97.4 µg/L after surgery.

After a significant delay because of postoperative recovery and wound healing, combined positron-emission tomography (PET)–computed tomography (CT) and contrast-enhanced CT imaging in September 2005 in advance of chemotherapy showed a 15-mm hypermetabolic subcutaneous mass in the right axillary region and multiple metastatic lymph nodes and peritoneal implants. The patient received 12 cycles of FOLFIRI, given every 2 weeks from October 2005 to March 2006. A combined PET–CT imaging study in April 2006 showed reduced metabolic activity, but stable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. A small chemotherapy pause was authorized; however, serum CEA rapidly rose over the subsequent weeks, and PET–CT imaging in June 2006 demonstrated disease progression with 2 new intra-abdominal lesions, 1 along the psoas muscle and 1 along the right hepatic artery. Second-line chemotherapy with 8 cycles of FOLFOX6 was given every 2 weeks from June to September 2006. Serum CEA declined slightly after the first 3 cycles and then rose again under chemotherapy (to 16 µg/L from 23.5 µg/L, and then to 29 µg/L). A
control PET–CT study in October 2006 demonstrated further disease progression of the right psoas muscle mass up to 4 cm.

For patient convenience, and also because of an early oxaliplatin-attributed sensory neuropathy, a switch was made to oral capecitabine 1250 mg/m² twice daily for 14 days every 3 weeks. In March 2007, the PET–CT showed tumour progression, and serum CEA was rising to 139 µg/L, but the patient was asymptomatic, and capecitabine was maintained. Control imaging in September 2007 revealed further enlargement of the known lesions and new psoas and peritoneal masses. The patient was experiencing right groin pain necessitating continuous opioid-based analgesia, together with limited right hip mobility. Serum CEA continued to rise, reaching a high of 552 µg/L.

Capecitabine was stopped, and the patient received two courses of palliative radiotherapy (20 Gy in 5 fractions each time) in September and December 2007 for right groin and flank pain and reduced functional capacity.

In February 2008, awaiting bevacizumab approval, the patient received 2 cycles of FOLFIRI, without significant clinical improvement. He then received 10 cycles of bevacizumab (5 mg/kg) every 2 weeks in addition to FOLFIRI. Post-treatment evaluation showed near-normal functional capacity. The pain had resolved, and the patient was no longer taking analgesics. Serum CEA dropped markedly to 24 µg/L, and new PET–CT imaging showed diminished metabolic activity and reduced sizes of most of the lymph nodes and metastatic implants, qualifying for a partial response according to RECIST criteria (Figure 1).

At November 2008, the patient was still on treatment, asymptomatic and in good general and functional status.

3. DISCUSSION AND CONCLUSIONS

Currently, seven chemotherapy drugs have been approved for patients with mCRC: 5FU, capecitabine, irinotecan, oxaliplatin, bevacizumab, cetuximab, and panitumumab. In the 1980s, 5FU was the only active drug for mCRC, and the addition of irinotecan and oxaliplatin improved response rate (RR), progression-free survival (PFS), and overall survival (OS). A similar scenario is happening with targeted agents that are already showing benefits and promising results.

Bevacizumab was the first targeted agent to be approved for routine use in mCRC. Most clinical trials so far have evaluated bevacizumab in the first- and second-line settings, and data concerning its efficacy in third-line settings are scarce. The U.S. National Cancer Institute’s Treatment Referral Center Trial by Chen et al. reported low RR for third-line therapies using bevacizumab. Based on an assessment by the investigators, the RR was 4%, but an independent review evaluated the rate at 1%. The PFS was 3.5 months, and the OS was 9 months. Another trial presented by Emmanouilides et al. concluded that bevacizumab could result in disease stabilization and clinical benefit in a proportion of heavily pretreated patients, with a median time to progression of 16 weeks. The use and benefits of bevacizumab in salvage therapy for pretreated patients with refractory CRC are still unclear and must be assessed in randomized studies.

In June 2008, Shitara et al. reported on the efficacy and feasibility of bevacizumab-containing third-line chemotherapy in a patient with mCRC that had progressed under FOLFOX and FOLFIRI chemotherapy regimens. Similarly, a retrospective analysis of mCRC patients pretreated with FOLFIRI and FOLFOX and receiving salvage bevacizumab plus either FOLFIRI or FOLFOX demonstrated a RR of 9.5%. The median PFS and OS were 5.3 months and 9.5 months respectively.

Our data accords with the three latter reports. Our patient initially presented stable disease and then rapid tumour progression after first-line FOLFIRI chemotherapy, and despite further tumour progression under FOLFOX and capecitabine chemotherapy, he presented spectacular clinical improvement, reduction of tumour markers, and partial response on CT scan under bevacizumab–FOLFIRI third-line chemotherapy. All these data underline the potential role of bevacizumab-containing chemotherapy beyond second-line treatment, especially for patients who did not receive bevacizumab-containing first- or second-line chemotherapy. In such patients, the utility of bevacizumab-containing third-line therapy should be considered.

4. REFERENCES

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2008. Toronto: Canadian Cancer Society; 2008.
2. Cunningham D, Findlay M. The chemotherapy of colon cancer can no longer be ignored. *Eur J Cancer* 1993;29A:2077–9.

3. Rothenberg ML, Oza AM, Bigelow RH, et al. Superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. *J Clin Oncol* 2003;21:2059–69.

4. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. *Lancet* 1998;352:1413–18.

5. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. *Lancet* 1998;352:1407–12. [Erratum in: *Lancet* 1998;352:1634]

6. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. *J Clin Oncol* 2005;23:3502–8.

7. Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. *Ann Oncol* 2008;19:1141–5.

8. Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. *Ann Oncol* 2007;18:697–701.

9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337–45.

10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–42.

11. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. *J Clin Oncol* 2005;23:3697–705.

12. Saltz LB, Clarke S, Diaz–Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008;26:2013–19. [Errata in: *J Clin Oncol* 2008;26:3110 and *J Clin Oncol* 2009;27:653]

13. Consolidating gains in colorectal cancer: report of the Eastern Canadian Colorectal Cancer Consensus Conference 2007. *Oncol Exch* 2008;7:18–22.

14. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. *J Clin Oncol* 2006;24:3354–60.

15. Charmanouilides C, Pegram M, Robinson R, Hecht R, Kabbinavar F, Isacoff W. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. *Tech Coloproctol* 2004;8(suppl 1):s50–2.

16. Shitara K, Munakata M, Muto O, Sakata Y. Metastatic rectal cancer responding to third-line therapy employing bevacizumab after failure of oxaliplatin and irinotecan: case report. *Jpn J Clin Oncol* 2008;38:493–6.

17. Kang BW, Kim TW, Lee JL, et al. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. *Med Oncol* 2009;26:32–7.

18. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205–16.

**Correspondence to:** Rami Kotb, Division of Hematology, Sherbrooke University, 3001–12 Avenue Nord, Sherbrooke, Quebec J1H 5N4.

**E-mail:** rami.kotb@usherbrooke.ca

* Departments of Hematology and Oncology (Gaulin, Kotb, Beauregard), Nuclear Medicine (Turcotte), Clinical Pharmacy (Berard), Pathology (Sawan), Radiology (Schmutz), Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC.